Natural Health Products (NHPs) are regulated in Canada under a framework overseen by Health Canada's Non-prescription and Natural Health Products Directorate (NNHPD). Unlike U.S. dietary supplements, Canadian NHPs are treated as a subset of drugs, which means pre-market approval and ongoing compliance are required. This article (Part 1 of 3) focuses on licensing activities—what it takes to obtain a product licence (NPN) and the associated site licences. Part 2 will cover costs, and Part 3 will compare the Canadian path to the U.S. FDA approach and discuss strategy.
Key takeaway
To sell an NHP in Canada, a company must obtain an NPN and ensure the manufacturing or importing sites hold valid site licences. Success hinges on five pillars: (1) ingredient eligibility, (2) a fully disclosed formula with appropriate human evidence for safety and efficacy, (3) a risk-based specification and testing plan, (4) fit-for-purpose labeling aligned to Canada's monographs where possible, and (5) stability data supporting the expiry date—backed by clear post-licensing change control.
Why Canada feels different
- Regulatory status: NHPs are regulated as drug-like products, not foods or supplements.
- Pre-market control: Products must receive an NPN before sale, and labels must display it.
- Disclosure: Proprietary blends aren't permitted; full formula disclosure (actives and quantities) is required on the label and in the application.
NPN: what Health Canada reviews
1) Ingredient eligibility
- Ingredients must be permitted for NHP use. NNHPD maintains an ingredient database.
- If an ingredient is not listed, applicants can submit a dossier to support its inclusion (typically human datademonstrating safe use at the proposed dose, plus identity/quality information). Acceptance adds the ingredient to the database, but does not equal product approval.
2) Full formula (no proprietary blends)
- The complete quantitative formula must be revealed in the application and on label.
- Each active ingredient's role, dose, and form (e.g., extract ratio/standardization) must be clear.
3) Safety and efficacy evidence
- Applicants submit full-text scientific articles (not abstracts) to justify safety, dosage, and claims.
- NNHPD evaluates study design quality (randomization, controls, blinding), population, dose form, and relevance to the proposed product.
- Expect rounds of clarification: Health Canada may request claim refinements, dosing changes, new warnings, or additional data. Each response window is time-bound (often 30–60 days).
4) Specifications and testing plan
- Include finished-product specifications up front: identity, purity, strength/assay, composition, microbiologicallimits, contaminants (e.g., heavy metals, pesticides where relevant), allergens, and packaging integrity.
- State methods, units, and pass/fail limits appropriate to the dosage form (capsule, powder, liquid, etc.).
5) Label content and packaging
- Submit complete label text for review: health claims, directions for use, contraindications, cautions/warnings, expiry date format, tamper-evident features, lot coding, and bilingual requirements.
- Health Canada assesses the net impression of labeling alongside the evidence.
Fast-track vs. bespoke: Class 1, 2, and 3 applications
Health Canada publishes monographs—pre-cleared ingredient and product categories with permitted doses, claims, and risk statements. These define application "classes":
- Class 1: Product fully attests to a single monograph (or combination monographs where allowed). Administrative review predominates; decisions can be relatively quick when aligned.
- Class 2: Product partially aligns with monographs (e.g., different non-medicinals, slight variance). Limited scientific review augments the administrative check.
- Class 3: Non-monograph or outside monograph limits (novel actives, new doses/claims, or unique combinations). Requires full evidence review and may involve multiple information requests—longer timelines.
Trade-off: Class 1/2 speed comes with less differentiation (similar claims/doses to competitors). Class 3 offers stronger uniqueness but demands more time, evidence, and cost.
Post-licensing obligations
Securing the NPN is the start—not the finish.
- Formula changes: Any change to actives, doses, standardizations, dosage form, or route may require notification or a formal amendment. Some changes invalidate the NPN and trigger a new application.
- Label updates: Adding claims, altering directions, modifying warnings, or changing origin statements typically require review.
- Manufacturer changes: Switching manufacturers, packagers, or testing labs touches the site licence landscape (see below) and may require updates.
- Change control discipline: Track, assess, and document changes; classify whether they are notification, amendment, or new application triggers.
Stability data and expiry dating
- The expiry date printed on pack must be substantiated with stability data.
- Expect a protocol (real-time and/or accelerated) with defined time points (e.g., 0, 3, 6, 9, 12, 18, 24 months) covering assay of actives, micro, organoleptics, and pack integrity under appropriate conditions.
- Budgets should reflect full panel testing at each time point; costs scale with number of actives and method complexity.
- Out-of-spec events require investigation, potential reformulation/overage strategy, label updates, or shelf-life reduction.
Site licences: manufacturer and importer responsibilities
Beyond the product licence (NPN), Health Canada requires site licences for relevant parties:
- Canadian manufacturers/packagers/labs: Must hold a site licence demonstrating GMP: SOPs, quality system, sanitation, training, calibration, recalls, deviations/CAPA, documentation, and validation where appropriate.
- Importers: If product is made outside Canada, the importer must hold a site licence and is accountable for ensuring the foreign site(s) meet equivalent GMP. Importers submit evidence packages (SOPs, certifications, audit reports) to support the licence.
- Accountability: When issues arise (e.g., test failures, stability gaps), Health Canada looks first to the importerinside Canada for records, testing, and corrective action.
Typical application package at a glance
- Forms: Product licence application + attestations (Class 1/2) or full evidence table (Class 3).
- Evidence: Full-text human studies, safety summaries, dose rationale, risk statements aligned to monographs or justified otherwise.
- Quality: Finished-product specifications (methods, limits), CM/pack/lab details, batch release plan.
- Labels: English/French text, claims, warnings, lot/expiry, tamper-evidence, storage, DIN-format formatting where applicable for NHPs.
- Stability: Protocol (or existing data) supporting the proposed shelf life.
- Sites: Site licence evidence (or commitments) for Canadian manufacturer/packer/lab and/or importer.
Quick FAQ
Can a proprietary blend be used to conceal exact amounts? No. Canada requires full disclosure of active ingredient quantities on label and in the dossier.
Are animal or in-vitro studies enough for claims? Not typically. Health Canada prioritizes human data relevant to the product's dose, form, and population.
How fast is a Class 1 application? When perfectly aligned to monographs and administratively clean, Class 1 can move significantly faster than Class 3—but timelines depend on Health Canada workload and completeness.
Is U.S. cGMP certification enough for a foreign CM? Helpful but not sufficient by itself. The Canadian importer must evidence that foreign sites meet NNHPD-recognized GMP and maintain ongoing qualification.
What's next in this series
- Part 2: Costs—licensing, stability, evidence development, site licensing, and ongoing compliance.
- Part 3: Canada vs. U.S.—pros/cons, speed vs. differentiation, and route-to-market strategy.